While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...

London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

European shares were flat in early trade on Wednesday, as gains led by healthcare stocks following drugmaker Novo Nordisk's ...

(Reuters) - European shares were flat in early trade on Wednesday, as gains led by healthcare stocks following drugmaker Novo ...

Stock prices in London were mixed on Wednesday afternoon, with a share price rise for GSK supporting the FTSE 100, though tariff worries continue to hang over equities. The FTSE 100 index rose 12.01 ...

European stocks remained flat in early trading Wednesday, as gains in healthcare were counterbalanced by a decline in ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

Wall Street was mostly lower on Wednesday despite US employment growth picking up last month by more than expected.

Mike Ralston, CEO of Blencowe Resources (BRES) and Manuel Pablo Zúñiga-Pflücker, President and CEO of PetroTal (PTAL) will be presenting and taking live Q&A at focusIR's Investor Webinar on Tuesday ...